Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in patients with refractory large B-cell lymphoma. As previously reported, prespecified clinical covariates for sec...

Full description

Bibliographic Details

Published in:	Blood advances Vol. 4; no. 19; pp. 4898 - 4911
Main Authors:	Locke, Frederick L., Rossi, John M., Neelapu, Sattva S., Jacobson, Caron A., Miklos, David B., Ghobadi, Armin, Oluwole, Olalekan O., Reagan, Patrick M., Lekakis, Lazaros J., Lin, Yi, Sherman, Marika, Better, Marc, Go, William Y., Wiezorek, Jeffrey S., Xue, Allen, Bot, Adrian
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 13.10.2020 American Society of Hematology
Subjects:	Antigens, CD19 - therapeutic use Humans Immunobiology and Immunotherapy Immunotherapy, Adoptive Inflammation Tumor Burden
ISSN:	2473-9529, 2473-9537, 2473-9537
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!